techConnect award logo
RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit
January 04, 2021 11:00 ET | RadioMedix Inc.
Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for...
Capture4
RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.
January 22, 2019 10:00 ET | RadioMedix Inc.
Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
radiomedix logo
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors
November 13, 2018 10:00 ET | RadioMedix Inc.
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
radiomedix logo
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
January 10, 2018 05:00 ET | RadioMedix Inc.
Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
radiomedix logo
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
June 22, 2017 16:00 ET | RadioMedix Inc.
Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) --  RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial  evaluating the biodistribution...
radiomedix logo
RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212
November 01, 2016 01:00 ET | RadioMedix Inc.
Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...